Hyperpolarized 129Xe MRI Lung Health Cohort

NCT ID: NCT05766384

Last Updated: 2025-04-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

260 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-30

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A subset of young adults participating in the American Lung Association (ALA) Lung Health Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and function. Images will be used to improve the understanding of lung health and early lung abnormalities that may lead to chronic lung disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyperpolarized Xe129

Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xenon, 129Xe, HP Xenon

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is enrolled in the American Lung Association Lung Health Cohort Study.
* Has completed CT imaging for the LHC study within 2 years of the scheduled Xe-MRI date.

Exclusion Criteria

* Pacemaker, internal defibrillator or other implanted electronic devices or any standard MRI contraindications (e.g., claustrophobia, \> 140 cm shoulder circumference, dependent on weight distribution).
* Is pregnant or breastfeeding
* Oxygen saturation (SpO2) \<88% on room air or with supplemental oxygen.
Minimum Eligible Age

25 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johns Hopkins University

OTHER

Sponsor Role collaborator

University of Iowa

OTHER

Sponsor Role collaborator

Duke University

OTHER

Sponsor Role collaborator

University of Illinois at Chicago

OTHER

Sponsor Role collaborator

Baylor College of Medicine

OTHER

Sponsor Role collaborator

Temple University

OTHER

Sponsor Role collaborator

University of Pennsylvania

OTHER

Sponsor Role collaborator

University of Kansas Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Peter J. Niedbalski, PhD

Research Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Illinois-Chicago

Chicago, Illinois, United States

Site Status NOT_YET_RECRUITING

University of Iowa

Iowa City, Iowa, United States

Site Status RECRUITING

University of Kansas Medical Center

Kansas City, Kansas, United States

Site Status RECRUITING

Duke University

Durham, North Carolina, United States

Site Status RECRUITING

Baylor College of Medicine

Houston, Texas, United States

Site Status NOT_YET_RECRUITING

MD Anderson Cancer Center

Houston, Texas, United States

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Cristal Monge

Role: CONTACT

913-945-9399

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Debby Cogley, MPH

Role: primary

312-996-9083

Eric Garcia

Role: primary

319-384-8610

Cristal Monge

Role: primary

913-945-9399

Kaitlin Foy

Role: primary

Laura Bertrand

Role: primary

713-798-4951

Jhankruti Desai, MPH

Role: primary

877-632-6789

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STUDY00160099

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Functional Applications of Hyperpolarized 129Xe MRI
NCT01697332 TERMINATED PHASE1/PHASE2
Genentech Xenon MRI Idiopathic Pulmonary Fibrosis
NCT04071769 ACTIVE_NOT_RECRUITING PHASE2
Comparison of 133Xe Scintigraphy With 19F MRI
NCT03532334 WITHDRAWN EARLY_PHASE1
Chronic Lung Allograft Dysfunction MRI Study
NCT06406777 RECRUITING PHASE1/PHASE2
Imaging Regional Lung Defect Severity
NCT01640288 COMPLETED PHASE1/PHASE2